Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer

Gynecologic Oncology

Volumn 124, Issue 2, 2012, Pages 319-324

  Fanning, James ^a   Hossler, Carrie A ^a   Kesterson, Joshua P ^a   Donahue, Renee N ^b   McLaughlin, Patricia J ^b   Zagon, Ian S ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Department of Neural and Behavioral Sciences ^*  (United States)

Author keywords

Opioid growth factor; Ovarian cancer

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; OPIATE RECEPTOR; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER PATIENT; CANCER SURGERY; CELL PROLIFERATION; CELL SURFACE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; ISOTOPE LABELING; MAJOR CLINICAL STUDY; METASTASIS; OVARIAN SURFACE EPITHELIAL CELL; OVARIECTOMY; OVARY; OVARY CANCER; OVARY CYST; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING;

ADULT; AGED; AGED, 80 AND OVER; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVARY; RECEPTORS, OPIOID;

EID: 84856018368     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.10.024     Document Type: Article

References (14)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. r axis utilizes the 16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation Mol Biol Cell 1 2009 319 327
3. I.S. Zagon, M.F. Verderame, and P.J. McLaughlin The biology of the opioid growth factor receptor (OGFr) Brain Res Rev 38 2002 351 376 (Pubitemid 34219111)
4. D.M. Avella, E.T. Kimchi, R.N. Donahue, H.R. Tagaram, P.J. McLaughlin, and I.S. Zagon The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer Am J Physiol Regul Integr Comp Physiol 298 2010 R459 R466
5. P.J. McLaughlin, D. Goldenberg, S.S. Park, A. Conway, R.N. Donahue, and I.S. Zagon Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) axis BMC Cancer 9 2009 369
6. J.R. Jaglowski, I.S. Zagon, B.C. Stack, M.F. Verderame, A.E. Leure-duPree, and J.D. Manning Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck Cancer Chemother Pharmacol 56 2005 97 104 (Pubitemid 41201762)
7. R.N. Donahue, P.J. McLaughlin, and I.S. Zagon Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis Am J Physiol Regul Integr Comp Physiol 296 2009 R1716 R1725
8. E.A. Hanna, S. Umhauer, S.L. Roshong, M.P. Piechocki, M.J. Fernstrom, and J. Fanning Gap junctional intercellular communication and connexin43 expression in human ovarian surface epithelial cells and ovarian carcinomas in vivo and in vitro Carcinogenesis 20 7 1999 1369 1373 (Pubitemid 29341463)
9. R.N. Donahue, I.S. Zagon, and P.J. McLaughlin The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition J Cancer Ther 2 2011 110 124
10. R.N. Donahue, P.J. McLaughlin, and I.S. Zagon The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice Gynecol Oncol 122 2011 382 388
11. R.N. Donahue, P.J. McLaughlin, and I.S. Zagon Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model Exp Biol Med 00 2011 1 15
12. R.N. Donahue, P.J. McLaughlin, and I.S. Zagon Low dose naltrexone (LDN) suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin Exp Biol Med 236 2011 883 895
13. J.P. Smith, R.L. Conter, S.I. Bingaman, H.A. Harvey, D.T. Mauger, and M. Ahmad Treatment of advanced pancreatic cancer with opioid growth factor: phase I Anti-Cancer Drugs 2004 203 209 (Pubitemid 38429411)
14. J.P. Smith, H. Stock, S. Bingaman, D. Mauger, M. Rogosnitzky, and I.S. Zagon Low-dose nalterxone therapy improves active Crohn's disease Am J Gastroenterol 102 2007 820 828 (Pubitemid 46496605)